Институт стволовых клеток человека ISKJ

Институт стволовых клеток человека Income Statement 2007-2025 | ISKJ

Annual Income Statement Институт стволовых клеток человека

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Revenue	1.37 B	1.14 B	1.18 B	1.08 B	836 M	645 M	494 M	390 M	311 M	359 M	420 M	317 M	262 M	193 M	146 M	96.8 M	65.5 M
Cost Of Revenue	402 M	260 M	290 M	310 M	164 M	79.5 M	92.4 M	67.2 M	47.4 M	29.5 M	16.5 M	32.9 M	28.6 M	2.41 M	4.91 M	1.95 M	415 K
Gross Profit	966 M	877 M	891 M	774 M	671 M	565 M	402 M	323 M	263 M	330 M	403 M	284 M	233 M	190 M	142 M	94.8 M	65.1 M
Gross Profit Ratio	0.71	0.77	0.75	0.71	0.8	0.88	0.81	0.83	0.85	0.92	0.96	0.9	0.89	0.99	0.97	0.98	0.99
General and Administrative Expenses	64.1 M	31.9 M	31.5 M	25.8 M	41.3 M	25.9 M	22.4 M	65.6 M	35.1 M	46.7 M	19.9 M	10.3 M	7.77 M	10.1 M	8.97 M	9.43 M	8.3 M
Selling And Marketing Expenses	166 M	72.5 M	61.9 M	43.9 M	38.9 M	29.9 M	46.1 M	52.6 M	63.3 M	27.2 M	22.7 M	29.9 M	15.6 M	16.3 M	7.28 M	7.66 M	11.3 M
Selling General And Administrative Expenses	603 M	104 M	93.3 M	69.7 M	80.2 M	55.8 M	68.5 M	118 M	98.4 M	73.9 M	42.5 M	40.2 M	23.4 M	26.4 M	16.3 M	17.1 M	19.6 M
Other Expenses	58.1 M	582 M	691 M	557 M	400 M	53.4 M	4.65 M	29.9 M	5.44 M	59.7 M	3.31 M	1.06 M	-905 K	144 M	95.6 M	71.3 M	37.3 M
Operating Expenses	691 M	766 M	795 M	629 M	507 M	515 M	459 M	460 M	358 M	381 M	361 M	314 M	216 M	177 M	114 M	88.6 M	57.3 M
Cost And Expenses	1.09 B	1.03 B	1.08 B	939 M	672 M	595 M	552 M	527 M	406 M	411 M	378 M	314 M	245 M	180 M	119 M	90.6 M	57.7 M
Interest Expense	-	67.8 M	50.7 M	40.2 M	41.5 M	30.2 M	30.8 M	27.1 M	8.65 M	11.9 M	18.5 M	5.45 M	414 K	302 K	356 K	215 K	40 K
Depreciation And Amortization	49.2 M	53.5 M	81.3 M	74.9 M	28.7 M	29.7 M	40.5 M	24 M	26.2 M	25 M	22.5 M	8.99 M	6.07 M	4.99 M	3.56 M	2.22 M	814 K
EBITDA	326 M	151 M	161 M	209 M	203 M	128 M	-2.71 M	-98.6 M	-58.9 M	37.1 M	64.3 M	10.8 M	25.7 M	15.8 M	53.7 M	11 M	8.89 M
EBITDA Ratio	0.24	0.13	0.15	0.2	0.25	0.2	-0.01	-0.21	-0.19	0.1	0.15	0.03	0.11	0.11	0.37	0.11	0.14
Operating Income	276 M	111 M	92.4 M	147 M	181 M	117 M	-58.1 M	-144 M	-95.5 M	-51.3 M	42.7 M	-11.8 M	16.6 M	7.1 M	27.4 M	6.21 M	7.34 M
Operating Income Ratio	0.2	0.1	0.08	0.14	0.22	0.18	-0.12	-0.37	-0.31	-0.14	0.1	-0.04	0.06	0.04	0.19	0.06	0.11
Income Before Tax	211 M	29.3 M	29.5 M	93.5 M	101 M	-53.8 M	-127 M	-150 M	-60.3 M	160 K	27.4 M	-142 M	19.2 M	9.47 M	50.1 M	8.57 M	8.04 M
Income Before Tax Ratio	0.15	0.03	0.02	0.09	0.12	-0.08	-0.26	-0.38	-0.19	0.0	0.07	-0.45	0.07	0.05	0.34	0.09	0.12
Income Tax Expense	16.7 M	6.23 M	-4.09 M	-9.93 M	-9.89 M	-35.6 M	-17.2 M	-18.7 M	2.22 M	16.8 M	10.7 M	7.67 M	-1.71 M	3.05 M	5.8 M	1.92 M	2.05 M
Net Income Ratio	0.12	0.04	0.03	0.1	0.1	-0.05	-0.21	-0.29	-0.17	-0.04	0.04	-0.47	0.07	0.03	0.3	0.07	0.09
Earnings Per Share, EPS	1.82	0.53	0.42	1.38	1.13	-0.46	-1.37	-1.48	-0.69	-0.18	0.2	-2	2.86	0.12	0.89	0.11	0.1
EPS Diluted	1.82	0.53	0.42	1.38	1.13	-0.46	-1.37	-1.48	-0.69	-0.18	0.2	-2	2.86	0.12	0.89	0.11	0.1
Weighted Average Shares Outstanding	92.8 M	86.9 M	80 M	75 M	75 M	75 M	75 M	75 M	75 M	75 M	75 M	75 M	71.5 M	60 M	60.1 M	61.3 M	61.6 M

All numbers in RUB currency

Quarterly Income Statement Институт стволовых клеток человека

	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q1
Revenue	373 M	373 M	374 M	374 M	311 M	311 M	309 M	309 M	260 M	260 M	624 B	312 M	557 B	278 M	557 B	315 M	631 B	227 M	453 B	225 M	192 M	192 M	176 M	176 M	147 M	147 M	142 M	125 M	112 B	115 B	105 M	82.6 M	109 M	93.6 M	79.4 B	79.4 B	76 M	76 M	92.6 B	92.6 B	87.1 M	106 M	102 M	102 M	121 M
Cost Of Revenue	93.1 M	93.1 M	119 M	119 M	82.1 M	82.1 M	132 M	132 M	96.5 M	96.5 M	439 B	120 M	404 B	111 M	404 B	161 M	477 B	33.1 M	256 B	62.3 M	39.2 M	39.2 M	26.1 M	26.1 M	35.7 M	35.7 M	39.9 M	12.6 M	31 M	39.8 M	19.8 M	22.2 M	42.9 M	12.7 M	36.5 M	36.5 M	23.7 M	23.7 M	25.2 M	25.2 M	17.8 M	70.6 M	13.5 M	13.5 M	42.6 M
Gross Profit	280 M	280 M	255 M	255 M	228 M	228 M	176 M	176 M	163 M	163 M	185 B	192 M	153 B	168 M	153 B	154 M	154 B	193 M	197 B	163 M	153 M	153 M	150 M	150 M	111 M	111 M	102 M	113 M	112 B	115 B	85.3 M	60.4 M	66.1 M	81 M	79.4 B	79.4 B	52.3 M	52.3 M	92.6 B	92.6 B	69.3 M	35 M	88.6 M	88.6 M	78 M
Gross Profit Ratio	0.75	0.75	0.681	0.681	0.736	0.736	0.572	0.572	0.629	0.629	0.296	0.616	0.274	0.602	0.274	0.489	0.244	0.854	0.435	0.724	0.797	0.797	0.852	0.852	0.756	0.756	0.719	0.899	1.0	1.0	0.811	0.731	0.606	0.865	1.0	1.0	0.688	0.688	1.0	1.0	0.796	0.331	0.868	0.868	0.647
General and Administrative Expenses	17.4 M	17.4 M	20.1 M	20.1 M	12 M	12 M	11 M	11 M	8.66 M	8.66 M	-	11.6 M	-	7.37 M	-	12.6 M	-	6.53 M	-	16.7 M	9.55 M	9.55 M	9.66 M	9.66 M	6.63 M	6.63 M	3.34 M	2.72 M	10.6 M	10.1 M	9.3 M	19.6 M	15.4 M	20 M	11.3 M	11.3 M	9.38 M	9.38 M	15.8 M	15.8 M	9.72 M	24.3 M	6.53 M	6.53 M	20.9 M
Selling And Marketing Expenses	52.7 M	52.7 M	39.2 M	39.2 M	43.4 M	43.4 M	34.4 M	34.4 M	22.6 M	22.6 M	-	32.6 M	-	19.8 M	-	24.4 M	-	15.6 M	-	18 M	11.1 M	11.1 M	5 M	5 M	16.6 M	16.6 M	20.1 M	11.6 M	18.3 M	6.14 M	8.33 M	16.2 M	21.5 M	8.81 M	23.6 M	23.6 M	11.8 M	11.8 M	12 M	12 M	4.33 M	7.47 M	10.7 M	10.7 M	5.7 M
Selling General And Administrative Expenses	177 M	177 M	149 M	149 M	156 M	156 M	135 M	135 M	117 M	117 M	121 B	134 M	111 B	115 M	111 B	107 M	163 B	98.3 M	101 B	90.1 M	98.5 M	98.5 M	81.5 M	81.5 M	93.8 M	93.8 M	23.4 M	14.3 M	92.4 M	95.6 M	17.6 M	35.8 M	36.9 M	28.8 M	70.2 M	70.2 M	51.1 M	51.1 M	73.2 M	73.2 M	66 M	31.7 M	76.5 M	76.5 M	26.6 M
Other Expenses	18.8 M	18.8 M	8.67 M	8.67 M	17 M	17 M	-19.5 M	-19.5 M	11.6 M	11.6 M	-278 B	30.4 M	-220 B	19 M	-212 B	15.5 M	-270 B	26.5 M	-201 B	15.1 M	18.3 M	18.3 M	-6.02 M	-6.02 M	17.3 M	17.3 M	-5.91 M	6.85 M	5.19 M	10.5 M	28.3 M	4.3 M	5.43 M	-8.11 M	3.68 M	3.68 M	2.63 M	2.63 M	-3.6 M	-3.6 M	8.14 M	70 M	9.91 M	9.91 M	-20.6 M
Operating Expenses	196 M	196 M	169 M	169 M	176 M	176 M	153 M	153 M	132 M	132 M	-157 B	165 M	-109 B	135 M	-101 B	124 M	-107 B	125 M	-101 B	109 M	117 M	117 M	89.4 M	89.4 M	112 M	112 M	115 M	101 M	100 M	112 M	120 M	138 M	112 M	89.8 M	81.6 M	81.6 M	61.5 M	61.5 M	85.9 M	85.9 M	76.4 M	31.7 M	88.4 M	88.4 M	26.6 M
Cost And Expenses	289 M	289 M	288 M	288 M	258 M	258 M	285 M	285 M	228 M	228 M	439 B	285 M	404 B	246 M	404 B	285 M	477 B	158 M	256 B	171 M	156 M	156 M	116 M	116 M	148 M	148 M	155 M	114 M	131 M	152 M	140 M	160 M	138 M	89.8 M	118 M	118 M	85.2 M	85.2 M	111 M	111 M	94.2 M	102 M	102 M	102 M	69.2 M
Interest Expense	-	-	-	-	-	-	-	-	-	-	35.6 B	-	28.1 B	-	28.1 B	-	34 B	-	16.2 B	-	-	-	-	-	-	-	8.39 M	8.05 M	-	-	16.7 M	2.84 M	3.9 M	3.64 M	-	-	-	-	-	-	-	3.79 M	-	-	4.49 M
Depreciation And Amortization	12.8 M	12.8 M	7.96 M	7.96 M	17.1 M	17.1 M	6.89 M	6.89 M	13.1 M	13.1 M	44.5 B	16.2 M	36.8 B	13 M	-8.28 B	13.9 M	-11.1 B	12.6 M	-19.8 B	10.5 M	11.1 M	11.1 M	2.23 M	2.23 M	12.3 M	12.3 M	20.8 M	9.2 M	782 K	9.27 M	5.18 M	7.82 M	4.44 M	6.55 M	6.39 M	6.39 M	5.57 M	5.57 M	5.23 M	5.23 M	6.16 M	71.1 M	6.35 M	6.35 M	-19.4 M
EBITDA	96 M	96 M	96.1 M	96.1 M	67.3 M	67.3 M	33.1 M	33.1 M	40.3 M	40.3 M	72.2 B	48.5 M	80.3 B	45.9 M	43.5 B	44.3 M	36.2 B	81.2 M	76.9 B	64.3 M	47.6 M	47.6 M	62.5 M	62.5 M	10.7 M	10.7 M	-55.4 M	32.7 M	-18.3 M	-27.4 M	3.4 M	-49.6 M	-58.8 M	-4.64 M	-32.2 M	-32.2 M	-3.61 M	-3.61 M	-11.5 M	-11.5 M	-961 K	74.4 M	8.46 M	8.46 M	32 M
EBITDA Ratio	0.258	0.258	0.257	0.257	0.217	0.217	0.107	0.107	0.155	0.155	0.116	0.156	0.144	0.165	0.078	0.14	0.057	0.358	0.17	0.285	0.247	0.247	0.355	0.355	0.073	0.073	0.021	0.232	-0.0	-0.0	0.006	-0.623	-0.54	-0.049	-0.0	-0.0	-0.048	-0.048	-0.0	-0.0	-0.011	0.704	0.083	0.083	0.265
Operating Income	83.2 M	83.2 M	85.4 M	85.4 M	52.4 M	52.4 M	23.7 M	23.7 M	31.8 M	31.8 M	27.7 B	26.7 M	43.5 B	32.9 M	51.8 B	30.4 M	47.3 B	68.6 M	96.7 B	53.8 M	36.4 M	36.4 M	60.2 M	60.2 M	-1.55 M	-1.55 M	-6.1 M	3.71 M	-19.1 M	-36.7 M	-38.9 M	-62.3 M	-46.3 M	3.88 M	-38.6 M	-38.6 M	-9.18 M	-9.18 M	-18.5 M	-18.5 M	-7.12 M	3.3 M	156 K	156 K	51.4 M
Operating Income Ratio	0.223	0.223	0.228	0.228	0.169	0.169	0.077	0.077	0.122	0.122	0.044	0.086	0.078	0.118	0.093	0.096	0.075	0.303	0.213	0.239	0.189	0.189	0.343	0.343	-0.011	-0.011	-0.043	0.03	-0.0	-0.0	-0.37	-0.755	-0.425	0.041	-0.0	-0.0	-0.121	-0.121	-0.0	-0.0	-0.082	0.031	0.002	0.002	0.426
Income Before Tax	50.7 M	50.7 M	84 M	84 M	21.7 M	21.7 M	-61 K	-61 K	14.7 M	14.7 M	11 B	3.95 M	23.7 B	10.8 M	23.7 B	6.46 M	13.3 B	40.3 M	80.5 B	18.8 M	31.9 M	31.9 M	-40.6 M	-40.6 M	13.7 M	13.7 M	-84.6 M	15.5 M	-28.9 M	-29.2 M	-18.5 M	-60.2 M	-62.7 M	-8.27 M	-39 M	-39 M	8.82 M	8.82 M	-20.8 M	-20.8 M	20.9 M	70.6 M	-11.7 M	-11.7 M	27.5 M
Income Before Tax Ratio	0.136	0.136	0.225	0.225	0.07	0.07	-0.0	-0.0	0.057	0.057	0.018	0.013	0.043	0.039	0.043	0.02	0.021	0.178	0.178	0.083	0.166	0.166	-0.231	-0.231	0.093	0.093	-0.595	0.124	-0.0	-0.0	-0.176	-0.73	-0.575	-0.088	-0.0	-0.0	0.116	0.116	-0.0	-0.0	0.24	0.668	-0.115	-0.115	0.228
Income Tax Expense	1.14 M	1.14 M	4.68 M	4.68 M	3.68 M	3.68 M	3.36 M	3.36 M	249 K	249 K	200 M	100 K	-4.29 B	2.14 B	-4.29 B	898 K	1.8 B	5.86 B	-11.7 B	5.47 B	528 K	528 K	14.6 M	14.6 M	3.21 B	3.21 B	-5.65 M	-9.68 M	2.16 M	282 K	-6.26 M	-11.9 M	403 K	-1 M	778 K	778 K	1.89 M	1.89 M	2.49 M	2.49 M	5.89 M	16.6 M	2.04 M	2.04 M	6.4 M
Net Income Ratio	0.112	0.112	0.183	0.183	0.051	0.051	0.034	0.034	0.048	0.048	0.017	-0.013	0.05	0.035	0.05	0.001	0.018	0.16	0.204	0.074	0.133	0.133	-0.192	-0.192	0.113	0.113	-0.585	0.198	-0.0	-0.0	-0.06	-0.506	-0.514	-0.078	-0.0	-0.0	0.108	0.108	-0.0	-0.0	0.192	0.511	-0.128	-0.128	0.175
Earnings Per Share, EPS	0.001	0.001	0.001	0.001	0.0	0.0	0.0	0.0	0.0	0.0	0.15	-	0.38	0.0	0.38	-	0.16	0.001	1.23 K	0.0	0.0	0.0	-0.0	-0.0	0.0	0.0	-1.11	0.33	-0.0	-0.0	-0.084	-0.56	-0.75	-0.097	-0.001	-0.001	0.0	0.0	-0.0	-0.0	0.0	0.72	-0.0	-0.0	0.28
EPS Diluted	0.001	0.001	0.001	0.001	0.0	0.0	0.0	0.0	0.0	0.0	0.15	-	0.38	0.0	0.38	-	0.16	0.001	1.23 K	0.0	0.0	0.0	-0.0	-0.0	0.0	0.0	-1.11	0.33	-0.0	-0.0	-0.084	-0.56	-0.75	-0.097	-0.001	-0.001	0.0	0.0	-0.0	-0.0	0.0	0.72	-0.0	-0.0	0.28
Weighted Average Shares Outstanding	73.9 B	73.9 B	75.3 B	75.3 B	74.2 B	74.2 B	88.8 B	88.8 B	86.3 B	86.3 B	73.4 B	85 B	72.8 B	75.8 B	72.8 B	75 B	72.8 B	75 B	75 M	75 B	75.5 B	75.5 B	75 B	75 B	75 B	75 B	75 M	75 M	75 B	75 B	75 M	75 M	-	75 M	75 B	75 B	75 B	75 B	75 B	75 B	75 B	75 M	75 B	75 B	75 M

All numbers in RUB currency

The income statement is one of the three key financial reports of a company Институт стволовых клеток человека (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

How much revenue the company earned
How much it spent on production, personnel, marketing, taxes, etc.
What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features

The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-	2.43 %	$ 254 M	Germany
Arbutus Biopharma Corporation ABUS	$ 4.78	2.03 %	$ 793 M	Canada
Aclaris Therapeutics ACRS	$ 3.06	5.34 %	$ 237 M	USA
AlloVir ALVR	-	4.14 %	$ 49.1 M	USA
Aptevo Therapeutics APVO	$ 0.96	-6.37 %	$ 265 K	USA
Alexion Pharmaceuticals, Inc. ALXN	-	-	$ 40.3 B	USA
Ascendis Pharma A/S ASND	$ 215.02	2.77 %	$ 5 B	Danmark
EyeGate Pharmaceuticals, Inc. EYEG	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	-	-18.52 %	$ 27.3 M	Britain
Alterity Therapeutics Limited ATHE	$ 3.09	-	$ 7.43 B	Australia
Biophytis SA BPTS	-	-13.47 %	$ 169 M	France
BioVie BIVI	$ 1.25	-4.2 %	$ 1.85 M	USA
ARCA biopharma ABIO	-	1052.0 %	$ 415 M	USA
Acasti Pharma ACST	-	4.01 %	$ 150 M	Canada
Adaptimmune Therapeutics plc ADAP	-	-15.15 %	$ 60.3 M	Britain
BioNTech SE BNTX	$ 95.39	1.32 %	$ 27.2 B	Germany
Aeglea BioTherapeutics AGLE	-	-	$ 1.01 B	USA
Albireo Pharma ALBO	-	-0.23 %	$ 916 M	USA
Alpine Immune Sciences ALPN	-	-	$ 2.17 B	USA
Ampio Pharmaceuticals AMPE	-	-11.43 %	$ 502 K	USA
Amphastar Pharmaceuticals AMPH	$ 27.0	2.08 %	$ 1.31 B	USA
Applied Molecular Transport AMTI	-	-	$ 10.1 M	USA
Anika Therapeutics ANIK	$ 9.51	1.22 %	$ 139 M	USA
Can-Fite BioPharma Ltd. CANF	$ 0.18	-25.71 %	$ 392 M	Israel
Arena Pharmaceuticals ARNA	-	-6.81 %	$ 3.04 B	USA
Athersys ATHX	-	3.77 %	$ 22.4 M	USA
Acer Therapeutics ACER	-	2.71 %	$ 14 M	USA
Catalyst Biosciences CBIO	$ 12.13	0.12 %	$ 799 M	USA
Avenue Therapeutics ATXI	-	-52.27 %	$ 4.45 M	USA
AVROBIO AVRO	-	1083.1 %	$ 745 M	USA
Axon Enterprise AXON	$ 590.57	-0.08 %	$ 44.7 B	USA
Ayala Pharmaceuticals AYLA	-	-	$ 7.46 M	Israel
Aytu BioScience AYTU	$ 2.5	-1.57 %	$ 15.7 M	USA
AstraZeneca PLC AZN	$ 92.54	0.43 %	$ 96.9 B	Britain
Acorda Therapeutics ACOR	-	-24.86 %	$ 820 K	USA
Brickell Biotech BBI	-	-5.38 %	$ 6.06 M	USA
Burford Capital Limited BUR	$ 9.02	-1.04 %	$ 1.48 B	Britain
BeiGene, Ltd. BGNE	-	0.49 %	$ 251 B	Cayman-islands
Biohaven Pharmaceutical Holding Company Ltd. BHVN	$ 10.62	0.85 %	$ 687 M	USA
Biogen BIIB	$ 176.58	1.01 %	$ 25.7 B	USA
Abeona Therapeutics ABEO	$ 5.46	2.94 %	$ 117 M	USA
Celldex Therapeutics CLDX	$ 26.83	0.92 %	$ 1.73 M	USA
ADiTx Therapeutics ADTX	$ 1.14	-9.52 %	$ 15 K	USA
Cellectar Biosciences CLRB	$ 2.63	-2.09 %	$ 32.1 M	USA
Bellicum Pharmaceuticals BLCM	-	-9.72 %	$ 5.89 M	USA
Berkeley Lights BLI	-	-7.31 %	$ 87 M	USA
Advaxis ADXS	-	-9.65 %	$ 45.9 M	USA
Завод ДИОД DIOD	-	-	-	Russia
Фармсинтез LIFE	-	-	-	Russia

Институт стволовых клеток человека Income Statement 2007-2025 | ISKJ

Annual Income Statement Институт стволовых клеток человека

Revenue

Cost Of Revenue

Gross Profit

Gross Profit Ratio

General and Administrative Expenses

Selling And Marketing Expenses

Selling General And Administrative Expenses

Other Expenses

Operating Expenses

Cost And Expenses

Interest Expense

Depreciation And Amortization

EBITDA

EBITDA Ratio

Operating Income

Operating Income Ratio

Income Before Tax

Income Before Tax Ratio

Income Tax Expense

Net Income Ratio

Earnings Per Share, EPS

EPS Diluted

Weighted Average Shares Outstanding